GlassScriptPhysician profile
Shannon James
NPI 1053898908
$9,622.41
in general payments reported to CMS, 2019-2025
22 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,453 · 2022: $2,542 · 2023: $2,107 · 2024: $1,775 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,547 · Education: $80.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,546.95 |
| Education | $80.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,573.36 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,561.72 | 2021-2025 | Caplyta |
| Alkermes, INC. | $987.83 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $833.77 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $731.58 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $703.39 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $589.69 | 2022-2025 | Auvelity |
| Corium, LLC | $388.34 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $327.43 | 2024-2025 | Cobenfy |
| Novo Nordisk INC | $325.31 | 2022-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $286.69 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Indivior INC. | $256.15 | 2021-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $249.05 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $180.67 | 2021-2022 | |
| Lundbeck LLC | $160.49 | 2022-2024 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $133.69 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $93.54 | 2022-2025 | Qelbree |
| Lilly USA, LLC | $78.72 | 2024 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $70.48 | 2021-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $48.72 | 2023 | Quviviq |
| Bausch Health US, LLC | $23.11 | 2023 | Aplenzin, Wellbutrin |
| Alfasigma USA, INC. | $18.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.